SARS-CoV-2 Spike Glycoprotein (D614G Mutation)
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Spike Glycoprotein, D614G Variant is a full-length recombinant protein expressed in HEK293 cells. It contains the foldon trimerization motif, mutated Furin recognition site and 2 stabilising mutations (K986P and V987P), based on/modified from Amanat et al, 2020.
The SARS-CoV-2 Spike Protein (S protein) is a viral protein that allows the entry of SARS-CoV-2 into human cells. The protein forms trimers on the viral capsid and binds to human Angiotensin Converting Enzyme 2 (ACE2) located on the cell surface. The protein has a cleavage site between the S1 and S2 subunits that is targeted by the human enzyme Furin, and it may also cause the development of a syncytium (cell fusion). Antibodies to S protein can prevent viral entry as well as target the virus for further immune action.
The SARS-CoV-2 Spike Protein (S protein) is a viral protein that allows the entry of SARS-CoV-2 into human cells. The protein forms trimers on the viral capsid and binds to human Angiotensin Converting Enzyme 2 (ACE2) located on the cell surface. The protein has a cleavage site between the S1 and S2 subunits that is targeted by the human enzyme Furin, and it may also cause the development of a syncytium (cell fusion). Antibodies to S protein can prevent viral entry as well as target the virus for further immune action.
| Supplier | Abbexa Ltd. |
|---|---|
| Product # | abx169319-100UG |
| Pricing | 100 µg USD $681.5 |
| Conjugation | Unconjugated |
| Host | HEK293 cells |
| Tested Applications | WB |
| UniProt Primary AC | P0DTC2 |
| Dry Ice | No |
| Availability | Shipped within 5-7 working days. |
| Note |
|